Namrata Sethi

Oncology

1900 NW Myhre Rd
Silverdale, WA 98383

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Claudin-6 as a potential target in the treatment of ovarian cancer: a review of emerging drugs.

Claudin-6 as a potential target in the treatment of ovarian cancer: a review of emerging drugs.

Journal: Expert opinion on emerging drugs

Published: July 17, 2026

Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes.

Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes.

Journal: Gynecologic oncology

Published: June 19, 2026

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression.

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression.

Journal: Gynecologic oncology reports

Published: June 03, 2026

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Journal: Gynecologic oncology

Published: May 29, 2026

Activity of datopotamab deruxtecan in TROP2-expressing low-grade serous ovarian cancer: a preclinical study.

Activity of datopotamab deruxtecan in TROP2-expressing low-grade serous ovarian cancer: a preclinical study.

Journal: Gynecologic oncology reports

Published: April 29, 2026

Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.

Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.

Journal: Gynecologic oncology

Published: December 02, 2025

Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis.

Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis.

Journal: Gynecologic oncology

Published: August 23, 2025

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor.

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor.

Journal: International journal of molecular sciences

Published: July 19, 2025

Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.

Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.

Journal: Gynecologic oncology

Published: July 02, 2025

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.

Journal: Gynecologic oncology

Published: May 10, 2025

Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.

Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.

Journal: Cancer research communications

Published: May 08, 2025

Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models.

Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 07, 2025

Showing 1-12 of 17

Last Updated: 09/26/2026